902 F.3d 1
1st Cir.2018Background
- Novartis held an original patent (Patent '184) claiming imatinib and its salts (expiring July 4, 2015) and later obtained Patent '051 covering a specific β‑crystalline form of imatinib mesylate (issued 2005, expires 2019).
- The PTO examiner rejected Novartis's β‑crystal claim as anticipated/obvious; the Patent Trial and Appeal Board reversed, and the PTO ultimately issued Patent '051 after Novartis submitted supplemental prior‑art citations disclosing imatinib mesylate (but not the β form).
- Generic manufacturers (e.g., Sun Pharma) filed ANDAs certifying Patent '051 was invalid; Novartis sued for infringement, producing litigation and settlements that delayed generic entry beyond July 4, 2015.
- Purchasers (direct and end‑payors) brought putative antitrust class actions alleging Novartis procured Patent '051 by fraud on the PTO (Walker Process) and pursued sham litigation to enforce it, seeking treble damages; Novartis moved to dismiss on Noerr‑Pennington immunity grounds.
- The district court dismissed for failure to state a claim, holding Noerr‑Pennington immunity applied because plaintiffs failed plausibly to plead the Walker Process (but‑for/materiality and intent) or PREI sham exceptions; the First Circuit affirmed.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Noerr‑Pennington bars antitrust claims based on enforcement of Patent '051 | Noerr immunity is inapplicable because exceptions (Walker Process fraud or sham litigation) apply | Noerr protects enforcement litigation; exceptions only if fraud (but‑for/material) or objectively baseless sham are plausibly alleged | Noerr applies; exceptions not plausibly pleaded, so dismissal affirmed |
| Walker Process: materiality of alleged misrepresentation that prior art did not disclose imatinib mesylate | Novartis falsely told PTO mesylate wasn’t in prior art; that misled PTO and was material to issuance | Patent covers a particular crystalline form (β), Board assumed mesylate was known and still reversed examiner; Novartis later submitted prior art and examiner considered it | Not material: issuance depended on β‑form distinction and later‑submitted prior art was considered; plaintiffs fail but‑for/material pleading |
| Walker Process: materiality of describing the β‑form as "surprising" (non‑obviousness) | "Surprising" mischaracterized routine, obvious result and was used to avoid obviousness rejection | Calling an invention "surprising" is a legal assertion of non‑obviousness for the examiner to evaluate, not a per se material misrepresentation | Not material: word "surprising" is legal argument, not an unmistakably false factual affidavit; plaintiffs failed to plead the high but‑for/materiality standard |
| PREI sham litigation: whether suit to enforce Patent '051 was objectively baseless | Patent was objectively invalid (anticipation/obviousness); so enforcement litigation was baseless and a sham | Patent had PTO/Board approval; presumption of validity and Board reversal of examiner make litigation reasonably viable | Not objectively baseless: patent presumption of validity and Board ruling show reasonable expectation of success; sham exception not plausibly pleaded |
Key Cases Cited
- United Mine Workers of Am. v. Pennington, 381 U.S. 657 (Sup. Ct.) (Noerr‑Pennington doctrine recognizes immunity for petitioning government)
- E. R.R. Presidents Conference v. Noerr Motor Freight, 365 U.S. 127 (Sup. Ct.) (First Amendment petitioning immunity principles)
- Prof'l Real Estate Inv'rs, Inc. v. Columbia Pictures Indus., Inc., 508 U.S. 49 (Sup. Ct.) (two‑part test for PREI sham litigation exception)
- Walker Process Equip., Inc. v. Food Mach. & Chem. Corp., 382 U.S. 172 (Sup. Ct.) (fraudulently procured patent can trigger antitrust liability)
- Microsoft Corp. v. i4i Ltd., 564 U.S. 91 (Sup. Ct.) (patent validity overturned only by clear and convincing evidence)
- Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir.) (materiality/egregious misconduct standard in inequitable‑conduct context)
- Dippin' Dots, Inc. v. Mosey, 476 F.3d 1337 (Fed. Cir.) (Walker Process pleading/materiality discussion)
- Sanofi‑Synthelabo v. Apotex, Inc., 550 F.3d 1075 (Fed. Cir.) (anticipation requires every claim element in single prior reference)